Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin
The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybinIn addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nauseaMydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing…